Simulations Plus, Inc. (NASDAQ:SLP) Receives $41.25 Consensus Target Price from Analysts

Shares of Simulations Plus, Inc. (NASDAQ:SLP) have received an average rating of “Buy” from the six brokerages that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $41.25.

SLP has been the topic of several recent analyst reports. Wall Street Zen upgraded Simulations Plus from a “sell” rating to a “hold” rating in a report on Monday, April 28th. KeyCorp lifted their price objective on Simulations Plus from $32.00 to $40.00 and gave the company an “overweight” rating in a report on Wednesday, April 16th. JMP Securities reissued a “market perform” rating on shares of Simulations Plus in a research note on Wednesday, June 18th. Craig Hallum dropped their target price on shares of Simulations Plus from $45.00 to $36.00 and set a “buy” rating on the stock in a report on Friday, June 13th. Finally, William Blair reiterated an “outperform” rating on shares of Simulations Plus in a report on Tuesday, June 3rd.

Simulations Plus Price Performance

Shares of NASDAQ:SLP opened at $17.91 on Tuesday. The stock has a market cap of $360.07 million, a price-to-earnings ratio of 51.16 and a beta of 0.83. The company has a 50 day moving average of $27.18 and a 200-day moving average of $28.93. Simulations Plus has a one year low of $16.72 and a one year high of $44.33.

Simulations Plus (NASDAQ:SLP) last released its earnings results on Thursday, April 3rd. The technology company reported $0.31 EPS for the quarter, topping analysts’ consensus estimates of $0.25 by $0.06. The firm had revenue of $22.43 million during the quarter, compared to analyst estimates of $21.93 million. Simulations Plus had a net margin of 9.18% and a return on equity of 7.86%. The business’s quarterly revenue was up 22.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.20 EPS. Equities research analysts anticipate that Simulations Plus will post 1.09 earnings per share for the current year.

Insider Activity

In other Simulations Plus news, Director Walter S. Woltosz sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $33.51, for a total value of $670,200.00. Following the sale, the director owned 3,344,157 shares in the company, valued at approximately $112,062,701.07. The trade was a 0.59% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 19.40% of the company’s stock.

Institutional Trading of Simulations Plus

A number of hedge funds and other institutional investors have recently made changes to their positions in SLP. Rhumbline Advisers increased its position in shares of Simulations Plus by 2.1% in the first quarter. Rhumbline Advisers now owns 66,222 shares of the technology company’s stock valued at $1,624,000 after acquiring an additional 1,334 shares during the last quarter. Woodline Partners LP grew its stake in Simulations Plus by 32.1% in the first quarter. Woodline Partners LP now owns 13,239 shares of the technology company’s stock valued at $325,000 after purchasing an additional 3,220 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in shares of Simulations Plus during the 1st quarter worth approximately $255,000. Uniplan Investment Counsel Inc. increased its position in shares of Simulations Plus by 141.8% during the 1st quarter. Uniplan Investment Counsel Inc. now owns 144,202 shares of the technology company’s stock worth $3,536,000 after purchasing an additional 84,562 shares during the last quarter. Finally, NFJ Investment Group LLC bought a new stake in shares of Simulations Plus during the 1st quarter worth approximately $1,254,000. 78.08% of the stock is currently owned by institutional investors and hedge funds.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.